Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

0.3011 -0.0289 (-8.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
From Cognition Therapeutics, Inc.
Via GlobeNewswire
November’s Small-Cap Treasures: 3 Stocks Poised for Growth
Three promising small-cap stocks, poised for growth in healthcare, cybersecurity, and renewable energy, offer compelling investment opportunities for November. 
Via MarketBeat
Topics Economy
Exposures Economy
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER’ clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 - 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning! 
Via InvestorPlace
Dow Edges Lower; Ventyx Biosciences Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
Via Benzinga
Exposures Fossil Fuels
Tivic Health Systems (TIVC) Stock Pops Another 39%
Tivic Health Systems stock is up on Monday with heavy trading of TIVC shares as recent volatility continues for the company's units. 
Via InvestorPlace
Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
Cognition Therapeutics' Phase 2 'SHINE' study shows CT1812 leads to cognitive improvement in Alzheimer's patients over six months. Participants showed better performance on cognitive and functional... 
Via Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
NLS Pharmaceutics stock is up on Monday after the company provided NLSP investors with details on a merger deal with Kadimastem. 
Via InvestorPlace
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report. 
Via InvestorPlace
Nasdaq Gains 1%; McDonald's Posts Downbeat Results
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning! 
Via InvestorPlace
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.